AI Drug Discovery Bottlenecked by Training Data, Not Compute, Startup Argues

Vivodyne, a Penn spinout backed by roughly $80M from Khosla Ventures, says AI drug-discovery models lack human-relevant training data, not compute or architecture. CEO Andrei Georgescu warns that without it, AI will only cure cancer in mice. About 90% of drugs effective in animal tests fail human approval. Anthropic's Dario Amodei has called AI cancer-cure claims more cliche than credible.